Analysis of outpatient administration of methotrexate for rheumatoid arthritis treatment
More details
Hide details
Online publication date: 2009-10-19
Reumatologia 2009;47(4):202-206
A group of 96 persons with rheumatoid arthritis (RA) who received methotrexate at a mean dose of 15 mg per week during their first hospitalization were sent questionnaires with the aim of assessing their GP’s attitude towards management of RA. Forty-eight replies were obtained. The results were: 44 patients continued treatment, 4 discontinued therapy for various reasons. No serious adverse effects were observed. Although most of the patients exhibited signs of heightened disease activity, the dosage was not modified in half of the group studied, 13 patients had the dosage reduced to the dosage level which is regarded as ineffective, only 2 had the dosage increased. None of the patients was administered the recommended methotrexate dose of 25 mg per week. Ineffectiveness of small doses of methotrexate resulted in prolonged treatment with corticosteroids. To summarize, the authors emphasize the need for the promotion of methotrexate treatment standards among physicians and their patients.
Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: Aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21 (Suppl 31): S209-S210. .
Tłustochowicz W, Brzosko M, Filipowicz-Sosnowska A i wsp. Stanowisko Zespołu Ekspertów Konsultanta Krajowego ds. Reumatologii w sprawie diagnostyki i terapii reumatoidalnego zapalenia stawów. Reumatologia 2008; 46: 111-114. .
Tłustochowicz W, Filipowicz-Sosnowska A, Kucharz EJ i wsp. Postępowanie z chorym na reumatoidalne zapalenie stawów w codziennej praktyce specjalisty reumatologa – wyniki ogólnopolskiego badania ankietowego. Reumatologia 2008; 46: 330-339. .
Cannon GW, Reading JC, Ward JR, et al. Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate. Scand J Rheumatol 1990, 19: 285-294. .
Willkens RF. Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis. Semin Arthritis Rheum 1990; 2: 76-80. .
Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs 1994; 47: 25-50. .
Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Result of two metaanalyses. Arthritis Rheum 1990; 33: 1449-1461. .
Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-1125. .
Goekoop-Ruiterman Y, de Vries-Bouwstra J, Allaart C, et al. Comparison of treatment strategies in early rheumatoid arthritis. Ann Int Med 2007; 166: 406-415. .
Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-269. .
Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-1255. .
Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-1874.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top